Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer (CORINNE-PI)
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: a Prospective, Randomised, Controlled, Multicentre Clinical Trial
Sponsor: RenJi Hospital
Listed as NCT05910398, this PHASE3 trial focuses on Breast Cancer Invasive and remains actively recruiting participants. Sponsored by RenJi Hospital, it has been updated 6 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE3
-
Oct 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Jul 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jun 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- RenJi Hospital
For direct contact, visit the study record on ClinicalTrials.gov .